Comar West Coast Ribbon Cutting Celebration

Comar, a premier supplier of specialty packaging solutions and custom molded medical devices and assemblies, was joined by customers, state and city government officials, members of the local Chamber of Commerce, their engineering partners at InterTech and Justin W. Capp, and their construction partners at Whiting Turner to commemorate the completion of its Rancho 2.0 Project with a ribbon-cutting ceremony at 9595 Utica Rd, Rancho Cucamonga, CA. The dedication took place on Monday, August 9th at 5:30pm.

The project consolidates employees, equipment, and operations from Comar’s existing Rancho Cucamonga and Garden Grove, California plants into a new state-of-the-art facility to support the incredible growth of our current and future customers.

The new 230,000 sq. ft. facility houses Injection Molding, Injection Blow Molding, and Injection Stretch Blow Molding cells and will be ISO 13485 certified, cGMP compliant, and FDA registered. Comar has added 50,000 sq. ft. of ISO Class 8 clean rooms and white rooms (Controlled Not-Classified) to support the manufacturing of diagnostic consumables, medical devices and sub-assemblies.

The site also has a full-service design, development, and prototyping center to complement Comar’s current east coast and mid-west innovation and development hubs.
Mike Ruggieri, CEO at Comar, said, “The dedication of the new Rancho Cucamonga facility is an inflection point for our organization. We dreamed of bringing together all our west coast capabilities under one roof and elevating them to the highest standards achievable. We believe this team has accomplished that and then some. It is an exciting space and will be a source of immense pride for our employees. For our customers in the medical and healthcare space, the investment will only advance our ability to deliver solutions that help them enhance and extend lives!”
In the past 18 months, Comar has been undergoing a period of rapid expansion, increasing its operational footprint by over 40% as it opens new manufacturing plants in New Jersey, Wisconsin, and California.
Visit us at MD&M West Expo / August 10-12, 2021 / Anaheim Convention Center / Anaheim, CA / Booth #1555

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”